Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

PURPOSE: The treatment of chronic lymphocytic leukemia (CLL) has been revolutionized by targeted therapies that either inhibit proliferation (ibrutinib) or reactivate apoptosis (venetoclax). Both significantly improve survival in CLL and replace chemoimmunotherapy for many patients. However, individ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Hillmen, Peter, Rawstron, Andy C., Brock, Kristian, Muñoz-Vicente, Samuel, Yates, Francesca J., Bishop, Rebecca, Boucher, Rebecca, MacDonald, Donald, Fegan, Christopher, McCaig, Alison, Schuh, Anna, Pettitt, Andrew, Gribben, John G., Patten, Piers E.M., Devereux, Stephen, Bloor, Adrian, Fox, Christopher P., Forconi, Francesco, Munir, Talha
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2019
Assuntos:
RAPID COMMUNICATION
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6879312/
https://ncbi.nlm.nih.gov/pubmed/31295041
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00894
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados